Wegovy Safety Signals & FDA Actions: What the Evidence Shows

How Semaglutide 2.4 mg Works

Semaglutide is a GLP-1 receptor agonist with 94% amino-acid homology to native human GLP-1. Its half-life of approximately 7 days allows once-weekly dosing, driven by albumin binding and resistance to dipeptidyl peptidase-4 degradation [1]. The drug activates GLP-1 receptors in the pancreas, gut, and brain. Pancreatic beta cells release more insulin in a glucose-dependent manner. Gastric emptying slows. Appetite-regulating neurons in the hypothalamus and brainstem shift energy balance toward satiety.

In STEP-1 (N=1,961), participants without diabetes receiving semaglutide 2.4 mg weekly lost a mean of 14.9% of body weight at 68 weeks, compared with 2.4% in the placebo group [2]. That magnitude of weight loss places semaglutide in a category previously achievable only with bariatric surgery. The FDA approved Wegovy for chronic weight management in June 2021, restricted to adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity [3].

Understanding how semaglutide works matters for interpreting its safety profile. GLP-1 receptors exist in the thyroid, pancreas, gallbladder, and kidneys. Each of those organs has generated a distinct safety signal.

The Boxed Warning: Thyroid C-Cell Tumors

The most prominent regulatory warning on the Wegovy label is a boxed warning for thyroid C-cell tumors. This is serious. In rodent studies, semaglutide caused dose-dependent and treatment-duration-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), at clinically relevant plasma exposures [3]. The FDA requires this warning for all GLP-1 receptor agonists because the entire drug class produces C-cell hyperplasia and tumors in rats and mice.

Human relevance remains uncertain. GLP-1 receptors are expressed at much lower density on human thyroid C cells than on rodent C cells [4]. A 2022 meta-analysis in Diabetes Care pooling data from seven randomized GLP-1 RA trials (N=60,540) found no statistically significant increase in thyroid cancer incidence with GLP-1 receptor agonist use (odds ratio 1.01 to 95% CI 0.58-1.75) [5]. The Endocrine Society's 2023 clinical practice guideline states: "There is no confirmed increased risk of medullary thyroid carcinoma in humans treated with GLP-1 receptor agonists, though long-term surveillance data remain limited" [6].

Wegovy is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2. Routine calcitonin monitoring is not recommended by the FDA for the general population prescribed semaglutide, but clinicians should be alert to symptoms such as a palpable thyroid nodule, dysphagia, or persistent hoarseness [3].

Gastrointestinal Adverse Events

GI side effects are the most common reason patients discontinue Wegovy. In STEP-1, nausea occurred in 44.2% of the semaglutide group versus 17.4% on placebo, diarrhea in 30.0% versus 15.7%, and vomiting in 24.8% versus 6.4% [2]. Most GI events were mild to moderate. They peaked during dose escalation (weeks 1 through 16) and attenuated over time.

The 5-week dose-escalation schedule (0.25 mg to 0.5 mg to 1.0 mg to 1.7 mg to 2.4 mg) was designed to mitigate these effects. Even so, 4.5% of semaglutide-treated participants in STEP-1 discontinued due to GI adverse events, compared with 0.8% on placebo [2]. In real-world observational data from the FDA Adverse Event Reporting System (FAERS), GI events account for the largest share of Wegovy-related reports [7].

Clinicians managing GI tolerability should confirm that patients are following the dose-escalation protocol. Extending time at a lower dose before uptitrating is an FDA-acknowledged strategy when GI symptoms are persistent. Small, frequent meals and adequate hydration reduce symptom burden for many patients, though no randomized trial has formally tested these behavioral modifications as adjuncts to semaglutide.

Pancreatitis: Signal vs. Confirmed Risk

Acute pancreatitis has been a pharmacovigilance focus for GLP-1 receptor agonists since the early exenatide era. The Wegovy prescribing information lists acute pancreatitis as a warning and precaution [3]. In pooled STEP trial data, acute pancreatitis occurred in 0.2% of semaglutide-treated patients versus 0.1% of placebo-treated patients. Small numbers make definitive risk quantification difficult.

The SELECT trial (N=17,604), the largest semaglutide outcomes study to date, reported acute pancreatitis in 0.2% of the semaglutide group and 0.2% of the placebo group over a mean follow-up of 39.8 months [8]. This parity in the largest available dataset is reassuring but does not exclude a small absolute risk increase in susceptible individuals.

The FDA recommends discontinuing Wegovy if pancreatitis is suspected and not restarting it if pancreatitis is confirmed. Patients with a history of pancreatitis should be observed closely. Lipase or amylase elevations alone, without clinical symptoms, do not mandate discontinuation [3].

Gallbladder Disease

Rapid weight loss of any cause increases gallstone formation. GLP-1 receptor agonists may add a pharmacologic contribution by slowing gallbladder motility. In STEP-1, cholelithiasis occurred in 1.5% of semaglutide patients versus 0.5% of placebo patients [2]. Cholecystitis was reported in 0.5% versus 0% [2].

The FDA updated the Wegovy label in 2022 to include acute gallbladder disease as a specific warning, noting that "substantial or rapid weight loss can increase the risk of cholelithiasis" and that "GLP-1 receptor agonists have been associated with cholelithiasis and cholecystitis" [3]. In SELECT, gallbladder-related disorders occurred in 2.8% of semaglutide patients versus 2.3% of placebo patients, a modest but consistent signal [8].

Patients who develop right upper quadrant pain, fever, or jaundice during Wegovy therapy need prompt evaluation. Ultrasonography is first-line. Clinicians should have a low threshold for gallbladder workup in any semaglutide-treated patient losing weight rapidly, defined as more than 1.5 kg per week sustained over multiple weeks.

Suicidal Ideation: The 2023 FDA Review

In July 2023, the FDA announced it was evaluating reports of suicidal ideation and self-injurious behavior in patients using GLP-1 receptor agonists, including semaglutide and liraglutide [9]. The European Medicines Agency (EMA) conducted a parallel review. This investigation was prompted by approximately 60 reports of suicidal ideation or self-harm submitted to international pharmacovigilance databases.

The FDA completed its preliminary evaluation in January 2024 and stated: "Our preliminary evaluation has not found evidence that use of these medicines causes suicidal thoughts or actions" [10]. The agency noted that GLP-1 receptor agonists are frequently prescribed to patients with obesity, a population with higher baseline rates of depression and suicidality than the general population.

A retrospective cohort study published in JAMA Internal Medicine in 2024, using electronic health records from over 240,000 patients prescribed semaglutide or tirzepatide, found no increased risk of suicidal ideation compared with matched controls (hazard ratio 0.73 to 95% CI 0.64-0.84) [11]. The FDA has kept this as an ongoing monitoring item but has not added a suicidality warning to the Wegovy label. Dr. Patrizia Cavazzoni, then-director of the FDA's Center for Drug Evaluation and Research, stated during the review that the agency would "continue to monitor these reports and will communicate any new safety information" [10].

Acute Kidney Injury

Post-marketing reports have linked semaglutide to acute kidney injury (AKI), primarily in the context of severe dehydration from vomiting and diarrhea [3]. The prescribing information warns that patients with renal impairment may experience worsening renal function during treatment. In STEP-1, renal events were not a major signal, but the trial excluded patients with an eGFR below 15 mL/min/1.73 m² [2].

A 2023 pharmacovigilance analysis in the Annals of Internal Medicine reviewed FAERS data and identified a disproportionality signal for AKI with GLP-1 receptor agonists, though the authors emphasized that confounding by dehydration and pre-existing chronic kidney disease limited causal inference [12]. The practical takeaway: monitor renal function in patients experiencing prolonged GI symptoms, especially those on concurrent nephrotoxic medications such as NSAIDs, ACE inhibitors, or diuretics.

Paradoxically, GLP-1 receptor agonists may protect kidney function over the long term. The FLOW trial (N=3,533) studied semaglutide 1.0 mg in patients with type 2 diabetes and chronic kidney disease and demonstrated a 24% reduction in the primary kidney composite endpoint [13]. These renal-protective data apply to the lower, diabetes-indication dose. Whether semaglutide 2.4 mg confers similar renal benefits in patients without diabetes remains unproven.

The SELECT Trial: Cardiovascular Safety and Beyond

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was the key post-marketing cardiovascular outcomes trial for Wegovy. It enrolled 17,604 adults aged 45 or older with established cardiovascular disease, a BMI of 27 kg/m² or greater, and no diabetes [8]. Participants received semaglutide 2.4 mg or placebo weekly for a mean of 39.8 months.

The primary endpoint, a three-point composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (MACE), occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group (HR 0.80 to 95% CI 0.72-0.90, P<0.001) [8]. That 20% relative risk reduction was driven primarily by reductions in non-fatal myocardial infarction and non-fatal stroke.

Dr. A. Michael Lincoff, the study's lead investigator, noted: "This is the first trial to show that treating obesity itself, rather than just its metabolic consequences, reduces cardiovascular events" [8]. The FDA granted Wegovy a supplemental indication for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight in March 2024 [14]. This made Wegovy the first weight-management drug to carry a cardiovascular benefit claim.

Safety findings in SELECT were consistent with the STEP program. The rate of serious adverse events was 33.4% with semaglutide and 36.4% with placebo. Treatment discontinuation due to adverse events was 16.6% with semaglutide and 8.2% with placebo, with GI events remaining the most common cause [8].

FDA Label Evolution: 2021 to Present

The Wegovy label has undergone several updates since initial approval. Tracking these changes reveals how the FDA's understanding of semaglutide's risk profile has matured.

June 2021: Initial approval for chronic weight management. The label included a boxed warning for thyroid C-cell tumors, warnings for pancreatitis, gallbladder disease, hypoglycemia risk with concomitant insulin or sulfonylureas, heart rate increase, and suicidal behavior and ideation (as a general psychiatric monitoring recommendation) [3].

January 2022: Label update to reflect pediatric approval for adolescents aged 12 and older, based on the STEP TEENS trial (N=201), which showed 16.1% mean weight reduction with semaglutide versus 0.6% weight gain with placebo at 68 weeks [15].

March 2024: Supplemental approval for reduction of cardiovascular risk based on SELECT. The Indications and Usage section was expanded, and cardiovascular outcomes data from SELECT were incorporated into the Clinical Studies section [14].

Post-marketing updates: Periodic label revisions have refined language around renal impairment, drug interactions, and GI adverse event management. The FDA has also issued multiple safety communications about compounded semaglutide products, which are not FDA-approved and may carry additional risks related to formulation quality [16].

Post-Marketing Surveillance and Ongoing Monitoring

FAERS data through 2025 show that Wegovy generates one of the highest volumes of adverse event reports among injectable medications, a function of both its safety profile and its enormous prescribing volume [7]. The most frequently reported events remain GI (nausea, vomiting, diarrhea, constipation), followed by injection-site reactions, headache, and fatigue. Serious but rare reports include intestinal obstruction, gastroparesis, and ileus.

The FDA issued a safety communication in September 2023 specifically addressing reports of intestinal obstruction with GLP-1 receptor agonists [17]. Post-marketing case reports have described patients developing symptoms consistent with mechanical or functional bowel obstruction, though a causal relationship has not been confirmed. Clinicians should consider GLP-1 RA therapy as a potential contributing factor in any patient presenting with obstructive GI symptoms.

Novo Nordisk maintains an ongoing pharmacovigilance program and is required by the FDA to conduct several post-marketing studies. These include long-term thyroid cancer surveillance, assessment of pancreatic safety signals, and evaluation of cardiovascular outcomes in broader populations.

What Clinicians Should Monitor

A practical monitoring framework for Wegovy prescribers should include baseline and periodic assessment of the following: renal function (serum creatinine, eGFR) at baseline and during episodes of significant GI symptoms; thyroid examination if symptoms suggestive of thyroid nodules develop; lipase if pancreatitis is clinically suspected (not routinely); gallbladder evaluation if right upper quadrant symptoms arise; and psychiatric symptom screening, particularly in patients with pre-existing mood disorders.

Heart rate increases of 1 to 4 beats per minute have been observed with semaglutide in clinical trials [3]. While not clinically significant for most patients, those with baseline tachycardia or arrhythmias warrant monitoring. The FDA does not require routine ECG monitoring.

Dose modifications should follow the labeled escalation schedule. If a patient cannot tolerate the 2.4 mg maintenance dose, the 1.7 mg dose can be used as the maintenance dose. The FDA label does not endorse doses between 1.7 mg and 2.4 mg [3]. Prescribers should document the clinical rationale for any dose held or reduced due to adverse events, and patients reporting persistent vomiting for more than 72 hours should be evaluated for dehydration and renal function before continuing therapy.